Letybo (Botulinum Toxin Type A)

The toxin binds to nerve endings at the neuromuscular junction and cleaves the SNAP‑25 protein, which is essential for acetylcholine release. By blocking this neurotransmitter, the muscle cannot contract, resulting in a localized, reversible paralysis.

The dose of Letybo is determined by the prescribing clinician based on the specific indication, treatment area, patient characteristics, and desired clinical outcome. No fixed regimen is provided here; the prescriber sets the appropriate dosage.

Safety data for botulinum toxin type A in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To request Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Letybo contains the same active molecule—botulinum toxin type A—as other branded products. Differences may lie in formulation, vial size, approved indications, and regulatory status. Clinical efficacy and safety are generally comparable when used according to label‑recommended dosing and administration techniques.

Letybo should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and handle with aseptic technique to maintain sterility.

Letybo is given by intramuscular injection using a sterile needle. The injection sites and technique depend on the indication; for example, multiple small injections are used for facial cosmetic treatment, while larger doses may be injected into specific spastic muscles under guidance.

Serious risks include spread of toxin effect leading to dysphagia, respiratory compromise, generalized muscle weakness, and allergic reactions such as anaphylaxis. Prompt medical attention is required if symptoms of systemic weakness or difficulty breathing occur after injection.

Letybo is contraindicated in patients with known hypersensitivity to botulinum toxin type A or any of its excipients, and should be used with caution in individuals with neuromuscular disorders (e.g., myasthenia gravis), pregnant or breastfeeding women, and those taking medications that may potentiate neuromuscular blockade.